If you have been reading about carcinogenicity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
The NADH formed in the third oxidative step cannot be reoxidized in the peroxisome, so reducing equivalents are exported to the cytosol. β-oxidation in the peroxisome requires the use of a peroxisomal carnitine acyltransferase (instead of carnitine acyltransferase I and II used by the mitochondria) for transport of the activated acyl group into the mitochondria for further breakdown. The first oxidation step in the peroxisome is catalyzed by the enzyme acyl-CoA oxidase. The β-ketothiolase used in peroxisomal β-oxidation has an altered substrate specificity, different from the mitochondrial β-ketothiolase. Peroxisomal oxidation is induced by a high-fat diet and administration of hypolipidemic drugs like clofibrate.
On 23 May 2026, 12 militants were killed in fighting with the police forces in Bannu District, whereas a retired FCB personnel was also killed and four policemen and a child were injured in the clashes, the death toll rose to 25 militants, two policemen and two civilians, the next day while seven policemen and three civilians were injured, a 10kg IED was also defused. Punjab CTD also claimed to have captured and arrested 13 "suspected terrorists" in 58 raids throughout the province. On 24 May 2026, 11 TTP militants were killed in a series of operations in North Waziristan and two more in Lakki Marwat. Militants destroyed a school and a health center in Tank District.
===== Uruguay ===== In December 2024, Lula visited Uruguay to attend a Mercosur summit that culminated in the signing of the EU–Mercosur Association Agreement. He also met with former Uruguayan former president José Mujica, whom he decorated with the Order of the Southern Cross, Brazil's highest award, and president-elect Yamandú Orsi.
== Genetics == Mutation in the gene CAPN3, which encodes the protein calpain-3 (CAPN3), is the cause of calpainopathy. As of 2019, more than 480 CAPN3 mutations have been reported, some of which can be associated with severe or benign disease course. Usually, the disease follows an autosomal recessive inheritance pattern, requiring both CAPN3 alleles to be mutated for disease to occur. However, there can be CAPN3 mutations that follow an autosomal dominant inheritance pattern.
Sources: en.wikipedia.org
The xenon pit is a phenomenon of excess neutron absorption through 135Xe buildup in the reactor after a reduction in power or a shutdown and is often managed by letting the 135Xe decay away to a level at which neutron flux can be safely controlled via control rods again. A nuclear reactor will also produce much smaller amounts of 135Cs from the nonradioactive fission product 133Cs by successive neutron capture to 134Cs and then 135Cs. The thermal neutron capture cross section and resonance integral of 135Cs are 8.3 ± 0.3 and 38.1 ± 2.6 barns respectively. Disposal of 135Cs by nuclear transmutation is difficult, because of the low cross section as well as because neutron irradiation of mixed-isotope fission caesium produces more 135Cs from stable 133Cs. In addition, the intense medium-term radioactivity of 137Cs makes handling of nuclear waste difficult.
== History == The US Food and Drug Administration (FDA) approved sotagliflozin based on evidence from two clinical trials of 11,806 total participants with heart failure or with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The trials were conducted at 322 sites in 32 countries (SOLOIST/NCT03521934) and 750 sites in 42 countries (SCORED/NCT03315143) primarily in Europe, South America, and North America. Both trials were used for primary determination of the benefits and side effects of the drug. The benefits and side effects of sotagliflozin were evaluated in the two clinical trials. In both trials, participants were randomly assigned to receive either sotagliflozin or placebo by mouth once a day. Neither the participants nor the healthcare providers knew which treatment was being given until after the trial was completed. The benefit of sotagliflozin was evaluated by measuring the number of predefined events (death from cardiovascular causes, need for hospitalization for heart failure, or urgent medical care visit for heart failure) occurring in the patient population receiving sotagliflozin versus placebo.
His military friend was quoted as saying that their unit was allegedly deployed to South Ossetia for the exercises, but suddenly the war broke out. On 26 August 2008, Drug dlya druga reported that one mother was told by her son on 6 August that his company would be sent to South Ossetia on 9 August. At 3 am on 8 August her son was sent to Tskhinvali, where he was wounded. On 27 August 2008, Vecherny Saransk reported that Yunir Bikkinyaev, contract soldier of 135th Regiment, stopped to answer the phone calls on 7 August and his parents were worried. He later acknowledged he did so not to frighten his family. On 28 August 2008, Gazeta Yuga published a report about Zalim Gegraev, a wounded soldier from 1st company of the peacemaking battalion, who fought in South Ossetia. Gegraev's mother said that her son had told her that he was going to Tskhinvali before the war started. She also said that he had been to South Ossetia previously and when he was there, his phone did not work. Then Zalim spoke to journalist: "We had been there to participate in military exercises for a month in those areas before this. They ended, however we were not withdrawn. Then the order came to move to Tskhinvali. On 8 August we were near the town and waited for further instructions. I didn't even think that I could see such thing..."
Sources: en.wikipedia.org
Through pilot project funding, multidisciplinary mentorship, educational seminars, career development programs, and collaborative research opportunities, the Center provides early-stage investigators with the resources necessary to establish independent research programs. Junior faculty benefit from access to experienced mentors across multiple disciplines, specialized research cores, and opportunities to participate in multicenter studies and national collaborations. These efforts are closely integrated with the Barshop Institute's NIH-funded Biology of Aging Training Program (T32), creating a comprehensive environment for training predoctoral students, postdoctoral fellows, clinical fellows, and junior faculty in translational geroscience and geriatrics.
== Affinity chromatography == Selective enzyme and antibody separation can be achieved with the use of specific end groups that conjugate with the specific compounds. This results in a formation of a polymer-enzyme conjugate which can be reversibly precipitated and dissolved by changing the temperature. Chen and Hoffman used N-Hydroxysuccinimide (NHS) ester functional end group on NIPAAm to conjugate selectively with β-D-glucosidase. They found that the conjugated enzyme could be repeatedly precipitated and dissolved in solution and still maintain sufficient enzymatic activity. In a study that was published in 1998, Hoshino et al. prepared a TRP with a maltose ligand, evaluated it with concanavalin A (Con A), and attempted to separate and purify α-glucosidase, a thermolabile compound. Since the goal is to selectively isolate a thermolabile enzyme, a TRP with a small LCST value is desired. To fit this condition, the selected TRP was poly(N-acryloylpiperidine)-cysteamine (pAP), which has an LCST of 4 °C. The terminally bound maltose moiety maintains affinity for both analytes, thus the modified TRP, pAPM, met critical conditions of external temperature requirements and affinity for both target analytes. The solubility properties changed from 4 °C (soluble) to 8 °C (insoluble). Several reagents were tested for the recovery of Con A by desorption which had higher binding affinities to Con A than maltose. These reagents were α-D-glucopyranoside, D-mannose, methyl α-D-mannopyranoside, and glucose.
==== Signalling ==== In innate immunity TLRs play an important role. These TLRs (mainly TLR7 and TLR9) can be proteolytically activated by AEP. The reduction of proinflammatory cytokines by stimulating TLR9 was found in myeloid cells and plasmacytoid dendritic cells which lacked AEP. Enzyme is also important in processing of influenza virus and immune response using TLR7. AEP plays a critical role in TLR processing. and AEP can initiate removal of invariant chain in MHC-II complex, which can critically influence peptide generation and activity of MHCII.
In 2024, the United Nations General Assembly adopted the first global resolution on the promotion of "safe, secure and trustworthy" AI systems that emphasized the respect, protection and promotion of human rights in the design, development, deployment and the use of AI. In May 2024, the Department for Science, Innovation and Technology (DSIT) announced £8.5 million in funding for AI safety research under the Systemic AI Safety Fast Grants Programme, led by Christopher Summerfield and Shahar Avin at the AI Safety Institute, in partnership with UK Research and Innovation. Technology Secretary Michelle Donelan announced the plan at the AI Seoul Summit, stating the goal was to make AI safe across society and that promising proposals could receive further funding. The UK also signed an agreement with 10 other countries and the EU to form an international network of AI safety institutes to promote collaboration and share information and resources. Additionally, the UK AI Safety Institute planned to open an office in San Francisco. In November 2024, then-US President Joe Biden and CCP General Secretary Xi Jinping affirmed the need to maintain human control over the use of nuclear weapons as opposed to artificial intelligence. As part of the National Defense Authorization Act for Fiscal Year 2025, Congress enacted the section 1638, "Sense of Congress with respect to use of artificial intelligence to support strategic deterrence", into the US Code of federal law.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.